AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended). An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of modulating angiogenesis in a tissue associated with a disease condition, wherein said packaging material comprises a label which indicates that said pharmaceutical composition ~~can be used~~is administered to a patient for treating disease conditions by modulating angiogenesis, and wherein said pharmaceutical composition comprises ~~a~~an isolated active or inactive Raf protein~~ or an oligonucleotide having a nucleotide sequence capable of expressing said protein~~; wherein the active Raf protein is selected from the group consisting of c-Raf (SEQ ID NO: 2), a protein having the amino acid sequence corresponding to residues 306 through 648 of SEQ ID NO: 2, and Raf-caax (SEQ ID NO: 7); and the inactive Raf protein is selected from the group consisting of a protein having the amino acid sequence corresponding to SEQ ID NO: 2 having an amino acid other than lysine at residue 375, and a protein having the amino acid sequence corresponding to residues 1 through 305 of SEQ ID NO: 2.

B2

Claim 2 (currently amended). The article of manufacture of claim 1 wherein ~~said Raf protein is~~the composition comprises an active Raf protein and said modulating potentiates angiogenesis.

Claims 3 (currently amended). The article of manufacture of claim 2 wherein said active Raf protein is ~~wild-type Raf~~cRaf (SEQ ID NO: 2).

Claim 4 (cancelled).

Claim 5 (currently amended). The article of manufacture of claim ~~4~~2 wherein said active Raf ~~fusion~~ protein is Raf-caax (SEQ ID NO: 7).

Claim 6 (original). The article of manufacture of claim 2 wherein said tissue has poor circulation.

Claims 7-13 (withdrawn).

Claim 14 (currently amended). The article of manufacture of claim 1 wherein said ~~administering comprises~~pharmaceutical composition is administered to a patient by

intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

Claim 15 (currently amended). The article of manufacture of claim 1 wherein said ~~administering comprises~~pharmaceutical composition is administered to a patient as a single dose intravenously.

Claim 16 (original). The article of manufacture of claim 1 wherein said pharmaceutical composition further comprises a liposome.

Claims 17-40 (withdrawn).

Claim 41 (currently amended). A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a therapeutic amount of ~~a Raf protein, said Raf protein having kinase activity~~ an isolated active Raf protein and a pharmaceutically acceptable carrier or excipient, wherein the isolated active Raf protein is selected from the group consisting of c-Raf (SEQ ID NO: 2), a protein having the amino acid sequence corresponding to residues 306 through 648 of SEQ ID NO: 2, and Raf-caax (SEQ ID NO: 7).

Claims 42-67 (withdrawn).